Payment overview · 2025
General Payments
$1,524.82
66 reported records · 18 companies
Healthcare provider profile · identity verified
Michael Luz Avaricio, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · OZONE PARK, NY · NPI 1639275084
Verified facts
What the public records show
CMS Open Payments records show Michael Luz Avaricio, MD received $1,524.82 in general payments during 2025 across 66 reported records.
Alnylam Pharmaceuticals Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Opsumit, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $253.86 | 16.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $232.30 | 15.2% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $203.19 | 13.3% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $202.51 | 13.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $101.26 | 6.6% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $74.58 | 4.9% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $72.85 | 4.8% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.31 | 3.7% | 6 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $54.28 | 3.6% | 2 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $39.70 | 2.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.68 | 2.3% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $35.34 | 2.3% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $32.44 | 2.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $31.42 | 2.1% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $28.88 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.44 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.12 | 1.6% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $16.66 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,524.82 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $253.86 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $232.30 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $203.19 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $101.26 | 4 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $85.16 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.09 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $74.58 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $56.31 | 6 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $54.28 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $35.68 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 294 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 143 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 156 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 107 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 91 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
91 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
156 | 47 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
294 | 80 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
77 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1099 | 368 |
| Losartan Potassium | Losartan Potassium | 811 | 263 |
| Montelukast Sodium | Montelukast Sodium | 801 | 298 |
| Atorvastatin Calcium | Atorvastatin Calcium | 748 | 254 |
| Metoprolol Succinate | Metoprolol Succinate | 706 | 216 |
| Meloxicam | Meloxicam | 625 | 241 |
| Omeprazole | Omeprazole | 528 | 186 |
| Bumetanide | Bumetanide | 443 | 146 |
| Famotidine | Famotidine | 432 | 173 |
| Gabapentin | Gabapentin | 379 | 145 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 354 | 116 |
| Fluticasone Propionate | Fluticasone Propionate | 315 | 126 |
| Azithromycin | Azithromycin | 307 | 186 |
| Eliquis | Apixaban | 294 | 80 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 282 | 94 |
| Mometasone Furoate | Mometasone Furoate | 280 | 102 |
| Prednisone | Prednisone | 276 | 141 |
| Alprazolam | Alprazolam | 268 | 119 |
| Xarelto | Rivaroxaban | 252 | 74 |
| Ibuprofen | Ibuprofen | 251 | 102 |
| Metformin Hcl | Metformin Hcl | 237 | 82 |
| Ranolazine Er | Ranolazine | 217 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 215 | 106 |
| Meclizine Hcl | Meclizine Hcl | 206 | 98 |
| Tramadol Hcl | Tramadol Hcl | 203 | 132 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 72 |
| Carvedilol | Carvedilol | 194 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 58 |
| Labetalol Hcl | Labetalol Hcl | 172 | 55 |
| Lisinopril | Lisinopril | 168 | 60 |
| Allopurinol | Allopurinol | 160 | 57 |
| Promethazine Hcl | Promethazine Hcl | 160 | 80 |
| Jardiance | Empagliflozin | 156 | 47 |
| Nebivolol Hcl | Nebivolol Hcl | 156 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 50 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 144 | 68 |
| Farxiga | Dapagliflozin Propanediol | 143 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 37 |
| Simvastatin | Simvastatin | 126 | 47 |
| Methylprednisolone | Methylprednisolone | 124 | 78 |
| Januvia | Sitagliptin Phosphate | 122 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 40 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 118 | 93 |
| Ezetimibe | Ezetimibe | 115 | 47 |
| Furosemide | Furosemide | 115 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 43 |
| Kerendia | Finerenone | 107 | 25 |
| Naproxen | Naproxen | 101 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 34 |
| Chlorthalidone | Chlorthalidone | 96 | 34 |
| Sertraline Hcl | Sertraline Hcl | 95 | 28 |
| Linzess | Linaclotide | 91 | 29 |
| Nifedipine Er | Nifedipine | 90 | 32 |
| Glimepiride | Glimepiride | 87 | 34 |
| Spironolactone | Spironolactone | 83 | 26 |
| Ozempic | Semaglutide | 79 | 20 |
| Entresto | Sacubitril/Valsartan | 77 | 24 |
| Telmisartan | Telmisartan | 77 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 49 |
| Lidocaine | Lidocaine | 75 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 73 | 23 |
| Valsartan | Valsartan | 65 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 14 |
| Folic Acid | Folic Acid | 59 | 27 |
| Colchicine | Colchicine | 58 | 19 |
| Atenolol | Atenolol | 57 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 29 |
| Mirtazapine | Mirtazapine | 50 | 18 |
| Donepezil Hcl | Donepezil Hcl | 48 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 48 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 23 |
| Digoxin | Digoxin | 47 | 18 |
| Torsemide | Torsemide | 47 | 13 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Irbesartan | Irbesartan | 42 | 13 |
| Enalapril Maleate | Enalapril Maleate | 38 | 14 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | suppressed |
| Pregabalin | Pregabalin | 36 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | 13 |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Edarbi | Azilsartan Medoxomil | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | 16 |
| Finasteride | Finasteride | 30 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 26 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | 11 |
| Brilinta | Ticagrelor | 23 | suppressed |
| Clonidine | Clonidine | 23 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Ofloxacin | Ofloxacin | 22 | 16 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 21 | 13 |
| Baclofen | Baclofen | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Verquvo | Vericiguat | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 15 |
| Nateglinide | Nateglinide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Opsumit | Macitentan | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,524.82 · 66 records | Alnylam Pharmaceuticals Inc. | AFREZZA, AIRSUPRA, AMVUTTRA, Attruby, Barostim Neo System, CAMZYOS, CAPVAXIVE, ELIQUIS, FARXIGA, FUROSCIX, JARDIANCE, Kerendia, LEQVIO, LINZESS, LOKELMA, NEXLETOL, OPSUMIT, TELEPATCH CARDIAC MONITOR, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, VERQUVO, VOQUEZNA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error